Current Edition

DNA

DNA vaccine spurs antibodies against a common Parkinson’s target in mice

The neuronal protein alpha-synuclein has long been a target for Parkinson’s disease research, but it has delivered mixed results across multiple different therapeutics. Now, a …

Continue Reading →
clinical

Fortuna Fix Announces Series B Financing, Adding Amgen Ventures and Macnguyen Family Office as Shareholders

Fortuna Fix, a private, clinical-stage Regenerative Medicine company is aiming to be the first to bring to the clinic a patient’s own neural stem cells …

Continue Reading →